Andrea Newsome

Andrea Newsome


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Critical Care Medicine
Verified
Journal Article
Closed access
ANAndrea Newsome
Andrea Newsome
DADeepak Ayyala
Deepak Ayyala
MRMegan A. Rech
Megan A. Rech
SBSarah B. Blackwell
Sarah B. Blackwell
JCJoshua Campbell
Joshua Campbell
TYTina Yoo
Tina Yoo
OBJECTIVES: Despite the established role of the critical care pharmacist on the ICU multiprofessional team, critical care pharmacist workloads are likely not optimized in the ICU. Medication regimen complexity (as measured by the Medication Regimen Complexity-ICU [MRC-ICU] scoring tool) has been proposed as a potential metric to optimize critical care pharmacist workload but has lacked robust external validation. The purpose of this study was to test the hypothesis that MRC-ICU is related to both patient outcomes and pharmacist interventions in a diverse ICU population. DESIGN: This was a multicenter, observational cohort study. SETTING: Twenty-eight ICUs in the United States. PATIENTS: Adult ICU patients. INTERVENTIONS: Critical care pharmacist interventions (quantity and type) on the medication regimens of critically ill patients over a 4-week period were prospectively captured. MRC-ICU and patient outcomes (i.e., mortality and length of stay [LOS]) were recorded retrospectively. MEASUREMENTS AND MAIN RESULTS: A total of 3,908 patients at 28 centers were included. Following analysis of variance, MRC-ICU was significantly associated with mortality (odds ratio, 1.09; 95% CI, 1.08–1.11; p < 0.01), ICU LOS (β coefficient, 0.41; 95% CI, 00.37–0.45; p < 0.01), total pharmacist interventions (β coefficient, 0.07; 95% CI, 0.04–0.09; p < 0.01), and a composite intensity score of pharmacist interventions (β coefficient, 0.19; 95% CI, 0.11–0.28; p < 0.01). In multivariable regression analysis, increased patient: pharmacist ratio (indicating more patients per clinician) was significantly associated with increased ICU LOS (β coefficient, 0.02; 0.00–0.04; p = 0.02) and reduced quantity (β coefficient, –0.03; 95% CI, –0.04 to –0.02; p < 0.01) and intensity of interventions (β coefficient, –0.05; 95% CI, –0.09 to –0.01). CONCLUSIONS: Increased medication regimen complexity, defined by the MRC-ICU, is associated with increased mortality, LOS, intervention quantity, and intervention intensity. Further, these results suggest that increased pharmacist workload is associated with decreased care provided and worsened patient outcomes, which warrants further exploration into staffing models and patient outcomes.

8 May 2019 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
MGMorgan E Gwynn
Morgan E Gwynn
MPMargaret O Poisson
Margaret O Poisson
JWJennifer L Waller
Jennifer L Waller
ANAndrea Newsome
Andrea Newsome
The purpose of this study was to develop and validate a novel medication regimen complexity–intensive care unit (MRC-ICU) scoring tool in critically ill patients and to correlate MRC with illness severity and patient outcomes. This study was a single-center, retrospective observational chart review of adults admitted to the medical ICU (MICU) between November 2016 and June 2017. The primary aim was the development and internal validation of the MRC-ICU scoring tool. Secondary aims included external validation of the MRC-ICU and exploration of relationships between medication regimen complexity and patient outcomes. Exclusion criteria included a length of stay of less than 24 hours in the MICU, active transfer, or hospice orders at 24 hours. A total of 130 patient medication regimens were used to test, modify, and validate the MRC-ICU tool. The 39-line item medication regimen complexity scoring tool was validated both internally and externally. Convergent validity was confirmed with total medications (p < 0.0001). Score discriminant validity was confirmed by lack of association with age (p = 0.1039) or sex (p = 0.7829). The MRC-ICU score was significantly associated with ICU length of stay (p = 0.0166), ICU mortality (p = 0.0193), and patient acuity (p < 0.0001). The MRC-ICU scoring tool was validated and found to correlate with length of stay, inpatient mortality, and patient acuity.

30 June 2019 in Journal of Pharmacy Practice
Verified
Journal Article
Open access
PDF file
WHW. Anthony Hawkins
W. Anthony Hawkins
SSSusan E. Smith
Susan E. Smith
ANAndrea Newsome
Andrea Newsome
JCJohn R. Carr
John R. Carr
Christopher M. BlandChristopher M. Bland
Christopher M. Bland
TBTrisha N. Branan
Trisha N. Branan
Intravenous fluids (IVFs) are the most common drugs administered in the intensive care unit. Despite the ubiquitous use, IVFs are not benign and carry significant risks associated with under- or overadministration. Hypovolemia is associated with decreased organ perfusion, ischemia, and multi-organ failure. Hypervolemia and volume overload are associated with organ dysfunction, delayed liberation from mechanical ventilation, and increased mortality. Despite appropriate provision of IVF, adverse drug effects such as electrolyte abnormalities and acid–base disturbances may occur. The management of volume status in critically ill patients is both dynamic and tenuous, a process that requires frequent monitoring and high clinical acumen. Because patient-specific considerations for fluid therapy evolve across the continuum of critical illness, a standard approach to the assessment of fluid needs and prescription of IVF therapy is necessary. We propose the principle of “fluid stewardship,” guided by 4 rights of medication safety: right patient, right drug, right route, and right dose. The successful implementation of fluid stewardship will aid pharmacists in making decisions regarding IVF therapy to optimize hemodynamic management and improve patient outcomes. Additionally, we highlight several areas of focus for future research, guided by the 4 rights construct of fluid stewardship.

1 June 2021 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
ANAndrea Newsome
Andrea Newsome
BMBrian Murray
Brian Murray
SSSusan E Smith
Susan E Smith
TBTodd Brothers
Todd Brothers
MAMohammad A Al-Mamun
Mohammad A Al-Mamun
JDJohn W Devlin
John W Devlin
What gets measured, gets improved. —Robert Sharma Every critically ill patient requires care by a critical care pharmacist (CCP) for best possible outcomes. Indeed, these highly trained professionals generate benefit through direct patient care (eg, pharmacist-driven protocols, medication monitoring, etc), participation on the intensive care unit (ICU) interprofessional team (eg, pharmacotherapy recommendations, team education, etc), and leadership in the development and implementation of quality improvement initiatives.1 However, clinical CCP services are not provided for all ICU patients, and CCP staffing models often vary substantially across ICUs in a given hospital and among ICUs in the United States.2-4 In this narrative review, we use a gap analysis approach to define current levels of clinical CCP services, identify barriers to reaching an optimal level of these services, and propose strategies focused on expanding clinical CCP services and justifying those that currently exist. The broad scope of beneficial activities performed by the CCP has been extensively reviewed and supported by a position statement from the American Society of Health-System Pharmacists (ASHP), the American College of Clinical Pharmacy (ACCP), and the Society of Critical Care Medicine (SCCM): the CCP is an essential member of the healthcare team for delivery of patient-centered care in the ICU.1

23 July 2019 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
ANAndrea Newsome
Andrea Newsome
SSSusan E. Smith
Susan E. Smith
TJTimothy W. Jones
Timothy W. Jones
ATAshley Taylor
Ashley Taylor
MBMegan A. Van Berkel
Megan A. Van Berkel
MRMarina Rabinovich
Marina Rabinovich
Introduction: Pharmacists are widely recognized members of the critical care health care team. However, unlike other health care professions, critical care pharmacists do not have standardized pharmacist to patient ratios that establish maximal cost‐efficiency while maintaining optimal patient safety. Though many prior recommendations claim a ratio of 1:15 for safe pharmacy practice, recommendations have ranged as low as 1:8 to as high as 1:30.Objectives: To determine critical care pharmacists' perceptions of pharmacist to patient ratios within the intensive care unit (ICU) and qualitatively and quantitatively describe critical care pharmacist work environments.Methods: A cross‐sectional survey of pharmacists was conducted to identify current pharmacist to patient ratios and identify pharmacist perceptions of the safety of these ratios. Responses were presented using descriptive statistics. Multiple linear regression was conducted to determine factors associated with perceptions of workload and patient safety.Results: The response rate was 11% (n = 185). The majority of respondents reported participating in activities beyond patient care. The majority of pharmacists cared for more than 15 patients daily (n = 155, 84%), and 16% took care of 15 or fewer patients. About 30% of pharmacists did not feel the pharmacist to patient ratio optimized patient safety, and over half reported perceptions overwork. A majority of participants (n = 130, 76%) expressed a need for additional critical care pharmacists at their institutions. Higher pharmacist to patient ratios were associated with increased perception of unsafe patient care −.343 (−.507 to −.180, P < .001).Conclusions: Heterogeneity exists among critical care pharmacy activities that may influence pharmacists' perceptions of workload and patient safety. Critical care pharmacists report that their institutions should have more critical care pharmacists. Pharmacists' perceptions of workload vary based on differences in their activities outside of patient care.

12 June 2019 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
ANAndrea Newsome
Andrea Newsome
SSSusan E. Smith
Susan E. Smith
WOWilliam J. Olney
William J. Olney
TJTimothy W. Jones
Timothy W. Jones
CFChristy C. Forehand
Christy C. Forehand
LCLindsey Coppiano
Lindsey Coppiano
Background: Clinical pharmacists are established members of the interprofessional patient care team, but limited guidance for the optimal utilization of pharmacy resources is available. Objective measurement of medication regimen complexity offers a novel process for evaluating pharmacist activity. The purpose of this study was to evaluate the relationship between medication regimen complexity, as measured by a novel medication regimen complexity scoring tool (MRC‐ICU), and both pharmacist interventions and drug‐drug interactions (DDIs).Methods: This was a multi‐center, prospective, observational study. The electronic medical record was reviewed to collect patient demographics, patient outcomes, and MRC‐ICU and modified MRC‐ICU (mMRC‐ICU) score at 24, 48 hours, and at discharge. Pharmacist interventions were recorded during the patients' intensive care unit (ICU) stay. DDIs were also evaluated at 24, 48 hours, and at discharge. Spearman's rank‐order correlation was used to determine any correlation between the MRC‐ICU score at each time point and the number of pharmacist interventions and DDIs.Results: A total of 153 patients were evaluated from both centers. The median MRC‐ICU at 24 hours was 11 (interquartile range [IQR] 7‐15). MRC‐ICU at 24 hours was correlated with interventions at 24 hours (rs .439, P <.001). Furthermore, MRC‐ICU was correlated with total DDIs (rs .4, P < .001). A modified version of the MRC‐ICU was also correlated with number of pharmacist interventions (P < .001) and DDIs (P < .001).Conclusions: Medication regimen complexity showed a relationship with number of pharmacist interventions and number of DDIs.